InstaPILL

Executive Summary

InstaPILL is a specialized Contract Development and Manufacturing Organization (CDMO) based in Bengaluru, India, focused on advanced lyophilized Orally Disintegrating Tablets (ODTs) via its proprietary InstaPill® technology platform. These patient-friendly dosage forms dissolve in 3-10 seconds without water, addressing the needs of pediatric, geriatric, and dysphagic populations across multiple therapeutic areas including CNS, gastroenterology, allergy & immunology, and psychiatry. Founded in 2020 and now at commercial stage, InstaPILL leverages a growing global demand for easy-to-administer drugs, particularly as the aging population and chronic disease prevalence rise. Its niche positioning as a CDMO dedicated solely to ODTs offers pharmaceutical partners a turnkey solution for formulation development and manufacturing, potentially reducing time-to-market and enhancing patient adherence. While the company is private and relatively early in its commercial trajectory, its technology platform and focus on underserved patient groups present significant growth opportunities in the expanding ODT market.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with Major Pharma60% success
• Q4 2026FDA Approval for First Client Product Using InstaPill Technology40% success
• Q1 2027Capacity Expansion or New Facility Announcement70% success